



- (51) **International Patent Classification:**
G06F 19/28 (2011.01)
- (21) **International Application Number:**
PCT/US2021/058999
- (22) **International Filing Date:**
11 November 2021 (11.11.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/112,972 12 November 2020 (12.11.2020) US
- (71) **Applicant:** MICRONOMA, INC. [US/US]; 6432 Ferris Square, San Diego, California 92121 (US).
- (72) **Inventors:** ADAMS, Eddie; c/o MICRONOMA, INC., 6432 Ferris Square, San Diego, California 92121 (US). MILLER-MONTGOMERY, Sandrine; c/o MICRONOMA, INC., 6432 Ferris Square, San Diego, California 92121 (US).
- (74) **Agent:** HEIDARI, Andrew Emon; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

- (54) **Title:** SYSTEMS AND METHODS TO IMPROVE THERAPEUTIC OUTCOMES




FIG. 1A

- (57) **Abstract:** Provided are system and methods to improve therapeutic agent outcomes based on microbial and/or non-microbial nucleic acid compositions.